Hisooka

[PharmaWire @PharmaWireNews]

An unfavorable overall survival trend in a phase 3 trial threatens to thwart AstraZeneca $AZN and Daiichi Sankyo’s $DSNKY bid to establish Enhertu as a first-line treatment for patients with HER2-mutant non-small cell lung cancer.

Treatment with Enhertu showed a preliminary 15% increased risk of death compared with Keytruda plus chemotherapy in the phase 3 study, according to results shared at the 2026 World Conference on Lung Cancer.
https://t.co/JvQo9XYWPN

[PharmaWire @PharmaWireNews]

Roche’s $ROP T-cell reported that Lunsumio met its primary endpoint in earlier-line follicular lymphoma in a phase 3 trial. The company did no share any specific data.

Detailed data could help doctors and industry watchers understand the Lunsumio doublet’s position against Incyte’s $INCY Monjuvi and AbbVie $ABBV and Genmab’s $GMAB Epkinly, both of which won FDA approvals for second-line FL last year in three-drug regimens with R2.
https://t.co/y9ZFtLvwUZ

[PharmaWire @PharmaWireNews]

The US FDA has approved Eli Lilly's $LLY drug combination, Inluriyo-Verzeni, to treat adults with a type of advanced breast cancer that has spread to other parts of the body.

The approval was based on a late-stage study of 159 patients with this type of advanced breast cancer.
https://t.co/MX4wf12oQ4

[PharmaWire @PharmaWireNews]

A group of independent pharmacies in Arkansas are suing Express Scripts, one of the largest pharmaceutical middlemen in the U.S.

The lawsuit is seeking hundreds of millions of dollars in damages for allegedly underpaying for tens of thousands of prescriptions. According to lawyers for the plaintiffs, the case is the first filed under a state law passed last year giving Arkansas pharmacies the ability to go after PBMs for reimbursing them below the acquisition cost of drugs.
https://t.co/We0oKD55w7

[The Precedent @theprecedentX]

The FDA cleared Ultragenyx's Fayuvi, a one-time gene therapy, as the first approved treatment for children with Sanfilippo syndrome type A, a rare and fatal genetic disease. The approval came two days ahead of the agency's target date.

The approval represents an important milestone for patients, but it also shifts attention from regulatory approval to access. One-time gene therapies for ultra-rare diseases can carry significant costs, raising questions around how companies, insurers and healthcare systems ensure breakthrough treatments are accessible to the small patient populations they are designed to serve.

[PharmaWire @PharmaWireNews]

Akeso $AKESF and Summit Therapeutics’ $SMMT ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment-naïve, PD-L1-positive advanced non-small cell lung cancer in a phase 3 trial.

The result marks another positive readout from ivonescimab, whose Keytruda head-to-head win two years ago on the trial’s primary endpoint of progression-free survival sparked a frenzy for similar PD-(L)1xVEGF bispecific antibodies.
https://t.co/WghD8IBWEl

[The Precedent @theprecedentX]

Newly released documents show Pfizer agreed to share revenue with HHS if it succeeds in raising drug prices abroad, part of its "most favored nation" pricing agreement. The contract surfaced via a Public Citizen FOIA lawsuit, not a Pfizer disclosure.

It raises an odd governance question: a deal framed publicly as lowering US drug costs also hands the government a cut of Pfizer's overseas price hikes.

[The Precedent @theprecedentX]

New ESC Congress data shows BridgeBio $BBIO's acoramidis (Attruby) drove clinically meaningful improvement in heart function for 54% of ATTR-CM patients at 30 months, versus 20% on placebo, a rare case of a therapy showing potential disease reversal, not just slowed progression.

The results strengthen BridgeBio's position in an increasingly competitive ATTR-CM market. With the company seeking to expand its ATTR franchise beyond a single product, the data also highlight how clinical differentiation will increasingly shape competition as more treatment options become available.

[Lex Commentary @LexCommentaryEN]

$BBIO granted 63,009 RSUs to 36 new hires under Nasdaq rules, highlighting continued expansion.

The move came as BridgeBio built momentum in ATTR-CM with Attruby, while its $13bn market cap reflected its growing biotech presence.

[Sari Wulandari @SariWuulandarii]

Kalau setelah hari yang melelahkan otot terasa pegal, nenek saya tidak membuat teh, melainkan kompres hangat.

[Alexaras @AlexarasGD]

Been trying out different workflows for AI UGC for a while. This is the best workflow I've used.

Videos cost cents, you can clone any video you find on TikTok/Reels and it's really consistent. https://t.co/3Bitw9CT3p

[Yieldcat @Yieldcatio]

$YCAT mint is live at https://t.co/IWJqMo8Ryy

ca: 2VrRQ3e32rf8YgTAccqXteAv5Z2dtR39Hx3A5oPyieLd

trading fees fund the Yieldcat treasury + $YCAT buybacks and burns

our goals: real revenue, hard asset backing, and solana products that deliver value directly to holders

more soon

[Sari Wulandari @SariWuulandarii]

Ada satu tanaman yang oleh pria Indonesia disebut pasak bumi - “akar bumi”.

[Sari Wulandari @SariWuulandarii]

Di Indonesia, ada minuman tradisional yang cukup unik yang dikenal di kalangan pria.

[Sari Wulandari @SariWuulandarii]

Halo, saya Sari Wulandari 🌿

Saya lahir di Yogyakarta dan kini tinggal di Jakarta. Sejak kecil, saya sudah dekat dengan jamu, rempah-rempah, tanaman, dan resep-resep keluarga yang diwariskan dari generasi ke generasi.

[PAPA CULT @Papa666cult]

😐 Two updates in PAPA CULT!

👤 Earn 0.01 $PAPA for every friend you invite. No extra conditions: invite a friend, get your reward.

🎲 You can now play Dice with bets starting from 0.1 $PAPA.

Invite your friends and join the game 👁

https://t.co/XOnqqLfm8Q

[Yieldcat @Yieldcatio]

beware of copycats

official launch will only be announced here or https://t.co/IWJqMo8jJ0

[CoinDepo @DepoCoin]

📊 CoinDepo Q2 2026 Report is live!

Another quarter of growth — with stronger profitability and a portfolio built to stay resilient through challenging market conditions.

In Q2 2026, CoinDepo reached:

💼 $238.9M in Assets Under Management
👥 112,943 active users
📈 $14.31M in gross investment income
💰 $1.74M in net operating income
💧 $11.47M in liquidity & operational reserves

While the broader crypto market remained under pressure, CoinDepo continued strengthening its defensive investment approach — increasing allocations to overcollateralised lending and real-world investments while reducing exposure to more market-sensitive strategies.

👉 Read the full Q2 2026 Report: https://t.co/JbM9TdFQub